Meeting
2021 ASCO Annual Meeting
Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.
Authors
Jiayong Liu
Beijing Cancer Hospital, Beijing, China
Jiayong Liu , Zhengfu Fan , Wei Guo , Tian Gao , Shu Li , Jie Xu , Chujie Bai , Ruifeng Xue , Lu Zhang , Lu Xie , Zhichao Tan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 11547)
DOI
10.1200/JCO.2021.39.15_suppl.11547
Abstract #
11547
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
Safety and efficacy of eribulin plus anlotinib in patients with advanced soft tissue sarcoma (ERAS): A multi-center phase II study.
First Author: Jie Liu
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Efficacy and safety of anlotinib combined with TACE among patients with intermediate and advanced-stage hepatocellular carcinoma (HCC).
First Author: Lin Zheng
Poster
2023 ASCO Annual Meeting
Efficacy of eribulin administered in combination with an immune checkpoint inhibitor (ICI) and anlotinib as salvage treatment for patients (pts) with advanced adult soft tissue sarcoma (STS).
First Author: Xi Guo
Poster
2023 ASCO Annual Meeting
Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis.
First Author: Shubham Pant